Informe nº Osteba D12-04. - Euskadi.net

4.5.6. Recomendaciones1. El uso de politerapia antipsicótica en pacientes con esquizofrenia resistente no se ve avalado por losestudios, si bien empiezan a aparecer resultados prometedores para algunas combinaciones.2. En la mayoría de ocasiones, la utilización de dos o más antipsicóticos a la vez en pacientes con esquizofreniaresistente no comporta más que el aumento del número, intensidad y gravedad de efectossecundarios.3. Es importante el desarrollo de planes terapéuticos personalizados, a largo plazo y sometidos a revisionesperiódicas.4.5.7. bibliografía1. Akdede B, Anil Yagcioglu AE, Alptekin K et al.A double-blind study of combination of clozapinewith risperidone in patients with schizophrenia:effects on cognition. J ClinPsychiatry. 2006; 67: 1.912-1.919.2. Alvarez E, Corripio I, Perez V. Tratamiento dela esquizofrenia resistente. En Trastornos Psicóticos.Editorial Ars Médica. Fundación Españolade Psiquiatría y Salud Mental. ISBN84-9751-223-5. Madrid 2007.3. Anil Yagcioglu AE, Kivircik Akdede BB, TurgutTI et al. A double-blind controlled study of adjunctivetreatment with risperidona in schizophrenicpatients partially responsive toclozapina: efficacy and safety. J ClinPsychiatry. 2005; 66: 63-72.4. Assion HJ, Reinbold H, Lemansky S et al. Amisulprideaugmentation in patients with schizophreniapartially responsive orunresponsive to clozapine. A randomised,double-blind, placebo-controlled trial. Pharmacopsychiatry.2008; 41:24-28.5. Barbui C, Signoretti A, Mule S et al. Does theaddition of a second antipsychotic drug improveclozapina treatment ? Schizophr Bull.2009; 35: 458-468.6. Chan J, Sweeting M. Combination therapywith nonclozapine atypical antipsychotic medication:a review of current evidence. JPsychopharmacol. 2007; 21: 657-664.7. Chang JS, Ahn Y-M, Park HJ et al. Aripiprazolaugmentation in clozapina treated patientswith refractory schizophrenia: an 8-week, randomiseddouble-blind, placebo controlledtrial. J Clin Psychiatry. 2008; 69: 720-731.8. Correll CU, Frederickson AM, Kane JM et al.Does antipsychotic polypharmacy increasethe risk for metabolic syndrome? SchizophrRes. 2007; 89:91-100.9. Correll CU. Antipsychotic polypharmacy. Part1: Shotgun approach or targeted cotreatment?J Clin Psychiatry. 2008; 69: 674-675.10. Correll CU. Antipsychotic polypharmacy. Part2: Why use 2 antipsychotics when 1 is notgood enough?. J Clin Psychiatry. 2008; 69:860-861.11. Correll CU, Rummel-Kluge C, Corves C et al.Antipsychotic combination vs monotherapyin schizophrenia: a meta-analysis of randomisedcontrolled trials. Schizophr Bull. 2009; 35:443-457.12. Englisch S, Zink M. Combined antipsychotictreatment involving clozapina and aripiprazol.Prog Neuropsychopharmacol BiolPsychiatry. 2008; 32: 1.386-1.39213. Freudenreich O, Goff DC. Antipsychotic combinationtharpy in schizophrenia. A review ofefficacy and risk of current combinations. ActPsychiatr Scand. 2002; 106: 323-330.14. Freudenreich O, Henderson DC, Walsh JP etal. Risperidone augmentation for schizophreniapartially responsive to clozapina: a doubleblind, placebo-controlled trial. Schizophr Res.2007; 92:90-94esTRaTegIas85